Absence of degeneration of adrenergic neurons after prolonged treatment with debrisoquin.
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001835:Body Weight; D003647:Debrisoquin / Q000494:pharmacology; D004299:Dopamine beta-Hydroxylase / Q000378:metabolism; D005724:Ganglia / Q000033:anatomy & histology; D005727:Ganglia, Spinal / Q000201:enzymology; D006325:Heart Atria / Q000033:anatomy & histology; D006651:Histocytochemistry; D007546:Isoquinolines / Q000494:pharmacology*; D008297:Male; D008854:Microscopy, Electron; D008856:Microscopy, Fluorescence; D009410:Nerve Degeneration / Q000187:drug effects*; D009638:Norepinephrine / Q000032:analysis; D010477:Perfusion; D051381:Rats; D012077:Renal Artery; D013233:Stellate Ganglion / Q000201:enzymology; D013564:Sympathetic Nervous System / Q000187:drug effects*; D009435:Synaptic Transmission / Q000187:drug effects; D013997:Time Factors; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D014649:Vas Deferens / Q000166:cytology / Q000187:drug effects
D000959:Antihypertensive Agents; D007546:Isoquinolines; D014446:Tyrosine 3-Monooxygenase; D004299:Dopamine beta-Hydroxylase; D003647:Debrisoquin; D009638:Norepinephrine